ConvaTec Group PLC 2022 AR2
The report highlights Convatec's strong financial and strategic progress in 2022, delivering a 1.7% increase in reported revenue to $2,073 million and expanding its adjusted operating profit margin to 19.5%. The company successfully executed its FISBE strategy, launching three new products and entering the high-growth wound biologics segment through the acquisition of Triad Life Sciences. Additionally, Convatec made significant progress on its ESG framework, Convatec Cares, reducing Scope 1 and 2 greenhouse gas emissions by 32% and achieving 40% female representation on its Board.
Company: ConvaTec Group PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2022
Type: AR2
Pages: 250
Back to company
ConvaTec Group PLC
Annual Report And Accounts
The report highlights Convatec's strong financial and strategic progress in 2022, delivering a 1.7% increase in reported revenue to $2,073 million and expanding its adjusted operating profit margin to 19.5%. The company successfully executed its FISBE strategy, launching three new products and entering the high-growth wound biologics segment through the acquisition of Triad Life Sciences. Additionally, Convatec made significant progress on its ESG framework, Convatec Cares, reducing Scope 1 and 2 greenhouse gas emissions by 32% and achieving 40% female representation on its Board.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees